Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma

Affiliations

Comment

Kenneth A Katz. JAMA Dermatol. 2018.

. 2018 Jul 1;154(7):850-851.

doi: 10.1001/jamadermatol.2018.1229.

No abstract available

Comment in

Problematic End Points in a Trial of Topical Fluorouracil, 5%, for Chemoprevention of Keratinocyte Carcinoma-Reply.
Weinstock MA, Lew RA, Shaw FM; Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (VAKCC) Group. Weinstock MA, et al. JAMA Dermatol. 2018 Jul 1;154(7):851-852. doi: 10.1001/jamadermatol.2018.1230. JAMA Dermatol. 2018. PMID: 29898230 No abstract available.

Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial.
Weinstock MA, Thwin SS, Siegel JA, Marcolivio K, Means AD, Leader NF, Shaw FM, Hogan D, Eilers D, Swetter SM, Chen SC, Jacob SE, Warshaw EM, Stricklin GP, Dellavalle RP, Sidhu-Malik N, Konnikov N, Werth VP, Keri JE, Robinson-Bostom L, Ringer RJ, Lew RA, Ferguson R, DiGiovanna JJ, Huang GD; Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (VAKCC) Group. Weinstock MA, et al. JAMA Dermatol. 2018 Feb 1;154(2):167-174. doi: 10.1001/jamadermatol.2017.3631. JAMA Dermatol. 2018. PMID: 29299592 Free PMC article. Clinical Trial.